Aflatoxin: A 50-year Odyssey of mechanistic and translational toxicology

Toxicological Sciences

Volumn 120, Issue SUPPL.1, 2011, Pages

  Kensler, Thomas W ^a,b   Roebuck, Bill D ^c   Wogan, Gerald N ^d   Groopman, John D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Aflatoxin; Biomarkers; Chemoprevention; Molecular epidemiology

Indexed keywords

AFLATOXIN; AFLATOXIN B1; AFLATOXIN B2; AFLATOXIN G1; AFLATOXIN G2; AFLATOXIN M1; ALUMINUM SODIUM SILICATE; CHLOROPHYLL; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DNA; GLUTATHIONE TRANSFERASE; GREEN TEA EXTRACT; NOVASIL; OLTIPRAZ; RNA; SULFORAPHANE; UNCLASSIFIED DRUG;

AFLATOXICOSIS; BIOLOGICAL MONITORING; CANCER MORTALITY; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; DNA BINDING; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPOXIDATION; EXPOSURE; GROWTH INHIBITION; HEPATITIS B VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KENYA; LIVER CELL CARCINOMA; MORBIDITY; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTHARVEST PERIOD; PREDICTIVE VALUE; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; TOXICOLOGY; VALIDATION PROCESS;

AFLATOXINS; ANIMALS; ENVIRONMENTAL EXPOSURE; FOOD CONTAMINATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; POISONS; PUBLIC HEALTH; TOXICOLOGY; TRANSLATIONAL RESEARCH;

HEPATITIS B VIRUS;

EID: 79952088976     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq283     Document Type: Review

References (136)

1. Adamson, R. H., Correa, P., Sieber, S. M., McIntire, K. R., and Dalgard, D. W. (1976). Carcinogenicity of aflatoxin B1 in rhesus monkeys: two additional cases of primary liver cancer. J. Natl Cancer Inst. 57, 67-78.
2. Afriyie-Gyawu, E., Mackie, J., Dash, B., Wiles, M., Taylor, J., Huebner, H., Tang, L., Guan, H., Wang, J. S., and Phillips, T. (2005). Chronic toxicological evaluation of dietary NovaSil clay in Sprague-Dawley rats. Food Addit. Contam. 22, 259-269.
3. Anonymous. (2004). Outbreak of aflatoxin poisoning-eastern and central provinces, Kenya, January-July 2004. MMWR Morb. Mortal Wkly. Rep. 53, 790-793.
4. Ansher, S. S., Dolan, P., and Bueding, E. (1983). Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity. Hepatology 3, 932-935.
5. Ansher, S. S., Dolan, P., and Bueding, E. (1986). Biochemical effects of dithiolthiones. Food Chem. Toxicol. 24, 405-415.
6. Asao, T., Buchi, G., Abdel-Kader, M., Chang, S., Wick, E., and Wogan, G. N. (1963). Aflatoxins B and G. J. Am. Chem. Soc. 85, 1706-1707.
7. Azziz-Baumgartner, E., Lindblade, K., Gieseker, K., Rogers, H. S., Kieszak, S., Njapau, H., Schleicher, R., McCoy, L. F., Misore, A., DeCock, K., et al. (2005). Case-control study of an acute aflatoxicosis outbreak, Kenya, 2004. Environ. Health Perspect. 113, 1779-1783.
8. Bailey, G. S., Loveland, P. M., Pereira, C., Pierce, D., Hendricks, J. D., and Groopman, J. D. (1994). Quantitative carcinogenesis and dosimetry inrainbow trout for aflatoxin B1 and aflatoxicol, two aflatoxins that form the same DNA adduct. Mutat. Res. 313, 25-38.
9. Bennett, R. A., Essigmann, J. M., and Wogan, G. N. (1981). Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. Cancer Res. 41, 650-654.
10. Bhat, R. V. and Krishnamachari, K. A. (1977). Follow-up study of aflatoxic hepatitis in parts of western India. Ind. J. Med. Res. 66, 55-58.
11. Blount, W. P. (1961). Turkey "X" disease. J. Br. Turkey Fed. 9, 55-58.
12. Bosch, F. X., and Munoz, N. (1988). Prospects for epidemiological studies on hepatocellular cancer as a model for assessing viral and chemical interactions. IARC Sci. Publ. 89, 427-438.
13. Breinholt, V., Hendricks, J., Pereira, C., Arbogast, D., and Bailey, G. (1995a). Dietary chlorophyllin is a potent inhibitor of aflatoxin B1 hepatocarcinogenesis in rainbow trout. Cancer Res. 55, 57-62.
14. Breinholt, V., Schimerlik, M., Dashwood, R., and Bailey, G. (1995b). Mechanisms of chlorophyllin anticarcinogenesis against aflatoxin B1: complex formation with the carcinogen. Chem. Res. Toxicol. 8, 506-514.
15. Bueding, E., Dolan, P., and Leroy, J. P. (1982). The antischistosomal activity of oltipraz. Res. Commun. Chem. Pathol. Pharmacol. 37, 293-303.
16. Bulatao-Jayme, J., Almero, E. M., Castro, M. C., Jardeleza, M. T., and Salamat, L. A. (1982). A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int. J. Epidemiol. 11, 112-119.
17. Busby, W. F. J., and Wogan, G. N. (1984). Aflatoxins. In Chemical Carcinogens (C. D. Searle, Ed.), pp. 945-1136. American Chemical Society, Washington, DC.
18. Cabral, J. R. P., and Neal, G. E. (1983). The inhibitory effects of ethoxyquin on The carcinogenic action of aflatoxin B1 in rats. Cancer Lett. 19, 125-132.
19. Campbell, A. D., Whitaker, T. B., Pohland, A. E., Dickens, J. W., and Park, D. L. (1986). Sampling, sample preparation, and sampling plans for foodstuffs for mycotoxin analysis. Pure Appl. Chem. 58, 305-314.
20. Campbell, T. C., Caedo, J. P., Jr., Bulatao-Jayme, J., Salamat, L., and Engel, R. W. (1970). Aflatoxin M1 in human urine. Nature 227, 403-404.
21. Chang, M. H., You, S. L., Chen, C. J., Liu, C. J., Lee, C. M., Lin, S. M., Chu, H. C., Wu, T. C., Yang, S. S., Kuo, H. S., et al. (2009). Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J. Natl Cancer Inst. 101, 1348-1355.
22. Chen, J. G., Parkin, D. M., Chen, Q. G., Shen, Q. J., Zhang, B. C., and Zhu, Y. R. (2003). Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J. Med. Screen 10, 204-209.
23. Chen, J. G., Zhu, J., Parkin, D. M., Zhang, Y. H., Lu, J. H., Zhu, Y. R., and Chen, T. Y. (2006). Trends in the incidence of cancer in Qidong, China, 1978-2002. Int. J. Cancer 119, 1447-1454.
24. Dashwood, R., Negishi, T., Hayatsu, H., Breinholt, V., Hendricks, J., and Bailey, G. (1998). Chemopreventive properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res. 399, 245-253.
25. Diallo, M. S., Sylla, A., Sidibe, K., Sylla, B. S., Trepo, C. R., and Wild, C. P. (1995). Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa. Nat. Toxins 3, 6-9.
26. Dinkova-Kostova, A. T., Fahey, J. W., Wade, K. L., Jenkins, S. N., Shapiro, T. A., Fuchs, E. J., Kerns, M. L., and Talalay, P. (2007). Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. Cancer Epidemiol. Biomarkers Prev. 16, 847-851.
27. Eaton, D. L., and Groopman, J. D. (1994). In The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance. Academic Press, Inc., San Diego, CA.
28. Egner, P. A., Gange, S. J., Dolan, P. M., Groopman, J. D., Munoz, A., and Kensler, T. W. (1995). Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. Carcinogenesis 16, 1769-1773.
29. Egner, P. A., Groopman, J. D., Wang, J. S., Kensler, T. W., and Friesen, M. D. (2006). Quantification of aflatoxin-B1-N7-guanine in human urine by highperformance liquid chromatography and isotope dilution tandem mass spectrometry. Chem. Res. Toxicol. 19, 1191-1195.
30. Egner, P. A., Wang, J. B., Zhu, Y. R., Zhang, B. C., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., Gange, S. J., Jacobson, L. P., et al. (2001). Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl. Acad. Sci. U.S.A. 98, 14601-14606.
31. Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., and Lozniewski, A. (2002). Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. U.S.A. 99, 7610-7615.
32. Fahey, J. W., and Kensler, T. W. (2007). Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. Chem. Res. Toxicol. 20, 572-576.
33. Fahey, J. W., Stephenson, K. K., Dinkova-Kostova, A. T., Egner, P. A., Kensler, T. W., and Talalay, P. (2005). Chlorophyll, chlorophyllin and related tetrapyrroles are significant inducers of mammalian phase 2 cytoprotective genes. Carcinogenesis 26, 1247-1255.
34. Feingold, B. J., Vegosen, L., Davis, M., Leibler, J., Peterson, A., and Silbergeld, E. K. (2010). A niche for infectious disease in environmental health: rethinking the toxicological paradigm. Environ. Health Perspect. 118, 165-172.
35. Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. Advance Access published on June 17, 2010; doi: 10.1002/ijc.5516.
36. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., and Eaton, D. L. (1994). Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res. 54, 101-108.
37. Gan, L. S., Skipper, P. L., Peng, X., Groopman, J. D., Chen, J. S., Wogan, G. N., and Tannenbaum, S. R. (1988). Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis 9, 1323-1325.
38. Gong, Y., Hounsa, A., Egal, S., Turner, P. C., Sutcliffe, A. E., Hall, A. J., Cardwell, K., and Wild, C. P. (2004). Postweaning exposure to aflatoxin results in impaired child growth: a longitudinal study in Benin, West Africa. Environ. Health Perspect. 112, 1334-1338.
39. Gong, Y. Y., Cardwell, K., Hounsa, A., Egal, S., Turner, P. C., Hall, A. J., and Wild, C. P. (2002). Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study. Br. Med. J. 325, 20-21.
40. Gopalan, C., Tulpule, P. G., and Krishnamurthi, D. (1972). Induction of hepatic carcinoma with aflatoxin in the rhesus monkey. Food Cosmet. Toxicol. 10, 519-521.
41. Groopman, J. D., Donahue, P. R., Zhu, J., Chen, J., and Wogan, G. N. (1985). Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl. Acad. Sci. U.S.A. 82, 6492-6496.
42. Groopman, J. D., Hall, A. J., Whittle, H., Hudson, G. J., Wogan, G. N., Montesano, R., and Wild, C. P. (1992a). Molecular dosimetry of aflatoxin-N 7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev. 1, 221-227.
43. Groopman, J. D., Hasler, J. A., Trudel, L. J., Pikul, A., Donahue, P. R., and Wogan, G. N. (1992b). Molecular dosimetry in rat urine of aflatoxin-N7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and immunoaffinity/high performance liquid chromatography. Cancer Res. 52, 267-274.
44. Groopman, J. D., Jiaqi, Z., Donahue, P. R., Pikul, A., Lisheng, Z., Jun-shi, C., and Wogan, G. N. (1992c). Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res. 52, 45-52.
45. Groopman, J. D., and Kensler, T. W. (1999). The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight? Carcinogenesis 20, 1-11.
46. Groopman, J. D., and Kensler, T. W. (2005). Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicol. Appl. Pharmacol. 206, 131-137.
47. Groopman, J. D., Trudel, L. J., Donahue, P. R., Marshak-Rothstein, A., and Wogan, G. N. (1984). High-affinity monoclonal antibodies for aflatoxins and their application to solid-phase immunoassays. Proc. Natl. Acad. Sci. U.S.A. 81, 7728-7731.
48. Gross-Steinmeyer, K., Stapleton, P. L., Tracy, J. H., Bammler, T. K., Strom, S. C., and Eaton, D. L. (2010). Sulforaphane- and phenethyl isothiocyanate-induced inhibition of aflatoxin B1-mediated genotoxicity in human hepatocytes: role of GSTM1 genotype and CYP3A4 gene expression. Toxicol. Sci. 116, 422-432.
49. Harris, C. C. (1994). Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol. Biomarkers Prev. 3, 1-2.
50. Henry, S. H., Bosch, F. X., Troxell, T. C., and Bolger, P. M. (1999). Policy forum: public health. Reducing liver cancer-global control of aflatoxin. Science 286, 2453-2454.
51. Hill, A. B. (1965). The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295-300.
52. Ilic, Z., Crawford, D., Egner, P. A., and Sell, S. (2010). Glutathione-Stransferase A3 knockout mice are sensitive to acute cytotoxic and genotoxic effects of aflatoxin B1. Toxicol. Appl. Pharmacol. 242, 241-246.
53. Jirousek, L. (1958). Uber das vorkommen von trithionen (1,2-dithiocyclopent-4-en-3-thione) in Brassicapflanzen. Naturwissenschaften 45, 386-387.
54. Jubert, C., Mata, J. E., Bench, G., Dashwood, R., Pereira, C., Tracewell, W., Turteltaub, K. W., Williams, D., and Bailey, G. (2009). Effects of chlorophyll and chlorophyllin on low-dose aflatoxin B1 pharmacokinetics in human volunteers. Cancer Prev. Res. 2, 1015-1022.
55. Kensler, T. W., Chen, J. G., Egner, P. A., Fahey, J. W., Jacobson, L. P., Stephenson, K. K., Ye, L. X., Coady, J., Wang, J. B., Wu, Y., et al. (2005). Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo Township, Qidong, People's Republic of china. Cancer Epidemiol. Biomarkers Prev. 14, 2605-2613.
56. Kensler, T. W., Egner, P. A., Davidson, N. E., Roebuck, B. D., Pikul, A., and Groopman, J. D. (1986). Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S -transferases. Cancer Res. 46, 3924-3931.
57. Kensler, T. W., Egner, P. A., Trush, M. A., Bueding, E., and Groopman, J. D. (1985). Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 6, 759-763.
58. Kensler, T. W., Gange, S. J., Egner, P. A., Dolan, P. M., Munoz, A., Groopman, J. D., Rogers, A. E., and Roebuck, B. D. (1997). Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomarkers Prev. 6, 603-610.
59. Kensler, T. W., Groopman, J. D., Sutter, T. R., Curphey, T. J., and Roebuck, B. D. (1999). Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem. Res. Toxicol. 12, 113-126.
60. Kensler, T. W., He, X., Otieno, M., Egner, P. A., Jacobson, L. P., Chen, B., Wang, J. S., Zhu, Y. R., Zhang, B. C., Wang, J. B., Wu, Y., et al. (1998). Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev. 7, 127-134.
61. Kensler, T. W., Qian, G. S., Chen, J. G., and Groopman, J. D. (2003). Translational strategies for cancer prevention in liver. Nat. Rev. Cancer 3, 321-329.
62. Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116.
63. Kew, M. C. (2002). Epidemiology of hepatocellular carcinoma. Toxicology 181-182, 35-38.
64. Krishnamachari, K. A., Bhat, R. V., Nagarajan, V., and Tilak, T. B. (1975). Hepatitis due to aflatoxicosis. An outbreak in Western India. Lancet 1, 1061-1063.
65. Lancaster, M. C., Jenkins, F. P., and Philp, J. M. (1961). Toxicity associated with certain samples of groundnuts. Nature 192, 1095-1096.
66. Lewis, L., Onsongo, M., Njapau, H., Schurz-Rogers, H., Luber, G., Kieszak, S., Nyamongo, J., Backer, L., Dahiye, A. M., Misore, A., et al. (2005). Aflatoxin contamination of commercial maize products during an outbreak of acute aflatoxicosis in eastern and central Kenya. Environ. Health Perspect. 113, 1763-1767.
67. Liby, K., Yore, M. M., Roebuck, B. D., Baumgartner, K. J., Honda, T., Sundararajan, C., Yoshizawa, H., Gribble, G. W., Williams, C. R., Risingsong, R., et al. (2008). A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. Cancer Res. 68, 6727-6733.
68. Liu, Y., and Wu, F. (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ. Health Perspect. 118, 818-824.
69. Lunn, R. M., Zhang, Y. J., Wang, L. Y., Chen, C. J., Lee, P. H., Lee, C. S., Tsai, W. Y., and Santella, R. M. (1997). p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 57, 3471-3477.
70. Luo, H., Tang, L., Tang, M., Billam, M., Huang, T., Yu, J., Wei, Z., Liang, Y., Wang, K., Zhang, Z. Q., et al. (2006). Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. Carcinogenesis 27, 262-268.
71. Lutz, W. K. (1987). Quantitative evaluation of DNA-binding data in vivo for low-dose extrapolations. Arch. Toxicol. (Suppl. 11), 66-74.
72. Lye, M. S., Ghazali, A. A., Mohan, J., Alwin, N., and Nair, R. C. (1995). An outbreak of acute hepatic encephalopathy due to severe aflatoxicosis in Malaysia. Am. J. Trop. Med. Hyg. 53, 68-72.
73. Marks, S. H. (1991). Analysis of a reported organosulfur, carcinogenesis inhibitor: 1,2-dithiole-3-thione in cabbage. J. Agric. Food Chem. 39, 893-895.
74. McCoy, L. F., Scholl, P. F., Sutcliffe, A. E., Kieszak, S. M., Powers, C. D., Rogers, H. S., Gong, Y. Y., Groopman, J. D., Wild, C. P., and Schleicher, R. L. (2008). Human aflatoxin albumin adducts quantitatively compared by ELISA, HPLC with fluorescence detection, and HPLC with isotope dilution mass spectrometry. Cancer Epidemiol. Biomarkers Prev. 17, 1653-1657.
75. McGlynn, K. A., Rosvold, E. A., Lustbader, E. D., Hu, Y., Clapper, M. L., Zhou, T., Wild, C. P., Xia, X. L., Baffoe-Bonnie, A., Ofori-Adjei, D., et al. (1995). Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. U.S.A. 92, 2384-2387.
76. Menkir, A., Brown, R. L., Bandyopadhyay, R., Chen, Z. Y., and Cleveland, T. E. (2006). A USA-Africa collaborative strategy for identifying, characterizing, and developing maize germplasm with resistance to aflatoxin contamination. Mycopathologia 162, 225-232.
77. Moyers, S. B., and Kumar, N. B. (2004). Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr. Rev. 62, 204-211.
78. Nesbitt, B. F., O'Kelly, J., Sargeant, K., and Sheridan, A. (1962). Aspergillus flavus and turkey X disease. Toxic metabolites of Aspergillus flavus. Nature 195, 1062-1063.
79. Ngindu, A., Johnson, B. K., Kenya, P. R., Ngira, J. A., Ocheng, D. M., Nandwa, H., Omondi, T. N., Jansen, A. J., Ngare, W., Kaviti, J. N., et al. (1982). Outbreak of acute hepatitis caused by aflatoxin poisoning in Kenya. Lancet 1, 1346-1348.
80. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
81. Peers, F. G., and Linsell, C. A. (1977). Dietary aflatoxins and human primary liver cancer. Ann Nutr. Aliment 31, 1005-1017.
82. Phillips, T. D., Afriyie-Gyawu, E., Williams, J., Huebner, H., Ankrah, N. A., Ofori-Adjei, D., Jolly, P., Johnson, N., Taylor, J., Marroquin-Cardona, A., et al. (2008). Reducing human exposure to aflatoxin through the use of clay: a review. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 25, 134-145.
83. Phillips, T. D., Lemke, S. L., and Grant, P. G. (2002). Characterization of claybased enterosorbents for the prevention of aflatoxicosis. Adv. Exp. Med. Biol. 504, 157-171.
84. Poirier, M. C., Santella, R. M., and Weston, A. (2000). Carcinogen macromolecular adducts and their measurement. Carcinogenesis 21, 353-359.
85. Probst, C., Njapau, H., and Cotty, P. J. (2007). Outbreak of an acute aflatoxicosis in Kenya in 2004: identification of the causal agent. Appl. Environ. Microbiol. 73, 2762-2764.
86. Qian, G. S., Ross, R. K., Yu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N., and Groopman, J. D. (1994). A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 3, 3-10.
87. Qin, G., Gopalan-Kriczky, P., Su, J., Ning, Y., and Lotlikar, P. D. (1997). Inhibition of aflatoxin B1-induced initiation of hepatocarcinogenesis in the rat by green tea. Cancer Lett. 112, 149-154.
88. Ramos-Gomez, M., Kwak, M. K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., and Kensler, T. W. (2001). Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98, 3410-3415.
89. Richard, J. L., Bennett, G. A., Ross, P. F., and Nelson, P. E. (1993). Analysis of naturally occurring mycotoxins in feedstuffs and food. J. Anim. Sci. 71, 2563-2574.
90. Roebuck, B. D., Johnson, D. N., Sutter, C. H., Egner, P. A., Scholl, P. F., Friesen, M. D., Baumgartner, K. J., Ware, N. M., Bodreddigari, S., Groopman, J. D., et al. (2009). Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat. Toxicol. Sci. 109, 41-49.
91. Roebuck, B. D., Liu, Y. L., Rogers, A. E., Groopman, J. D., and Kensler, T. W. (1991). Protection against aflatoxin B 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51, 5501-5506.
92. Ross, R. K., Yuan, J. M., Yu, M. C., Qian, G. S., Tu, J. T., Gao, Y. T., Henderson, B. E.,Wogan, G. N., and Groopman, J. D. (1992). Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339, 943-946.
93. Sabbioni, G., Skipper, P. L., Buchi, G., and Tannenbaum, S. R. (1987). Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis 8, 819-824.
94. Santella, R. M. (1999). Immunological methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiol. Biomarkers Prev. 8, 733-739.
95. Sargeant, K., Sheridan, A., O'Kelly, J., and Carnaghan, R. B. A. (1961). Toxicity associated with certain samples of groundnuts. Nature 192, 1096-1097.
96. Scholl, P., Musser, S. M., Kensler, T. W., and Groopman, J. D. (1996). Inhibition of aflatoxin Ml excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis 17, 1385-1388.
97. Scholl, P. F., and Groopman, J. D. (2008). Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence. Cancer Epidemiol. Biomarkers Prev. 17, 1436-1439.
98. Scholl, P. F., McCoy, L., Kensler, T. W., and Groopman, J. D. (2006a). Quantitative analysis and chronic dosimetry of the aflatoxin B1 plasma albumin adduct Lys-AFB1 in rats by isotope dilution mass spectrometry. Chem. Res. Toxicol. 19, 44-49.
99. Scholl, P. F., Musser, S. M., and Groopman, J. D. (1997). Synthesis and characterization of aflatoxin B1 mercapturic acids and their identification in rat urine. Chem. Res. Toxicol. 10, 1144-1151.
100. Scholl, P. F., Turner, P. C., Sutcliffe, A. E., Sylla, A., Diallo, M. S., Friesen, M. D., Groopman, J. D., and Wild, C. P. (2006b). Quantitative comparison of aflatoxin B1 serum albumin adducts in humans by isotope dilution mass spectrometry and ELISA. Cancer Epidemiol. Biomarkers Prev. 15, 823-826.
101. Shank, R. C., Bourgeois, C. H., Keschamras, N., and Chandavimol, P. (1971). Aflatoxins in autopsy specimens from Thai children with an acute disease of unknown aetiology. Food Cosmet. Toxicol. 9, 501-507.
102. Sieber, S. M., Correa, P., Dalgard, D. W., and Adamson, R. H. (1979). Induction of osteogenic sarcomas and tumors of the hepatobiliary system in nonhuman primates with aflatoxin B1. Cancer Res. 39, 4545-4554.
103. Simonich, M. T., Egner, P., Roebuck, B. D., Orner, G., Jubert, C., Pereira, C., Groopman, J. D., Kensler, T. W., Dashwood, R. H., Williams, D., et al. (2007). Natural chlorophyll inhibits aflatoxin B1 induced multi-organ carcinogenesis in the rat. Carcinogenesis 28, 1294-1302.
104. Strosnider, H., Azziz-Baumgartner, E., Banziger, M., Bhat, R. V., Breiman, R., Brune, M. N., DeCock, K., Dilley, A., Groopman, J., Hell, K., et al. (2006). Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ. Health Perspect. 114, 1898-1903.
105. Sun, Z., Lu, P., Gail, M. H., Pee, D., Zhang, Q., Ming, L., Wang, J., Wu, Y., Liu, G., Wu, Y., et al. (1999). Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30, 379-383.
106. Sylla, A., Diallo, M. S., Castegnaro, J., and Wild, C. P. (1999). Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat. Res. 428, 187-196.
107. Talalay, P., and Fahey, J. W. (2001). Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J. Nutr. 131, 3027S-3033S.
108. Tang, L., Tang, M., Xu, L., Luo, H., Huang, T., Yu, J., Zhang, L., Gao, W., Cox, S. B., and Wang, J. S. (2008). Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention. Carcinogenesis 29, 411-417.
109. Thorgeirsson, U. P., Dalgard, D. W., Reeves, J., and Adamson, R. H. (1994). Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Regul. Toxicol. Pharmacol. 19, 130-151.
110. Tilak, T. B. (1975). Induction of cholangiocarcinoma following treatment of a rhesus monkey with aflatoxin. Food Cosmet. Toxicol. 13, 247-249.
111. Turner, P. C., Collinson, A. C., Cheung, Y. B., Gong, Y., Hall, A. J., Prentice, A. M., and Wild, C. P. (2007). Aflatoxin exposure in utero causes growth faltering in Gambian infants. Int. J. Epidemiol. 36, 1119-1125.
112. Turner, P. C., Sylla, A., Gong, Y. Y., Diallo, M. S., Sutcliffe, A. E., Hall, A. J., and Wild, C. P. (2005). Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 365, 1950-1956.
113. Ueng, Y. F., Shimada, T., Yamazaki, H., and Guengerich, F. P. (1995). Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8, 218-225.
114. Van der Zijden, A. S., Blanche Koelensmid, W. A., Boldingh, J., Barrett, C. B., Ord, W. O., and Philp, J. (1962). Isolation in crystalline form of a toxin responsible for Turkey X disease. Nature 195, 1060-1062.
115. Van Ness, K. P., McHugh, T. E., Bammler, T. K., and Eaton, D. L. (1998). Identification of amino acid residues essential for high aflatoxin B1-8,9-epoxide conjugation activity in alpha class glutathione S-transferases through site-directed mutagenesis. Toxicol. Appl. Pharmacol. 152, 166-174.
116. Van Rensburg, S. J., Cook-Mozaffari, P., Van Schalkwyk, D. J., Van der Watt, J. J., Vincent, T. J., and Purchase, I. F. (1985). Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br. J. Cancer 51, 713-726.
117. Vatanasapt, V., Martin, N., Sriplung, H., Chindavijak, K., Sontipong, S., Sriamporn, S., Parkin, D. M., and Ferlay, J. (1995). Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol. Biomarkers Prev. 4, 475-483.
118. Wang, J. S., Luo, H., Billam, M., Wang, Z., Guan, H., Tang, L., Goldston, T., Afriyie-Gyawu, E., Lovett, C., Griswold, J., et al. (2005). Short-term safety evaluation of processed calcium montmorillonite clay (NovaSil) in humans. Food Addit. Contam. 22, 270-279.
119. Wang, J. S., Qian, G. S., Zarba, A., He, X., Zhu, Y. R., Zhang, B. C., Jacobson, L., Gange, S. J., Munoz, A., Kensler, T. W., et al. (1996a). Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 5, 253-261.
120. Wang, J. S., Shen, X., He, X., Zhu, Y. R., Zhang, B. C., Wang, J. B., Qian, G. S., Kuang, S. Y., Zarba, A., Egner, P. A., Jacobson, L. P., et al. (1999). Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl Cancer Inst. 91, 347-354.
121. Wang, L. Y., Hatch, M., Chen, C. J., Levin, B., You, S. L., Lu, S. N., Wu, M. H., Wu, W. P., Wang, L. W., Wang, Q., et al. (1996b). Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer 67, 620-625.
122. Wang, P., Afriyie-Gyawu, E., Tang, Y., Johnson, N. M., Xu, L., Tang, L., Huebner, H. J., Ankrah, N. A., Ofori-Adjei, D., Ellis, W., et al. (2008). NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 25, 622-634.
123. Wang, X. W., Hussain, S. P., Huo, T. I., Wu, C. G., Forgues, M., Hofseth, L. J., Brechot, C., and Harris, C. C. (2002). Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 181-182, 43-47.
124. Wild, C. P., Hudson, G. J., Sabbioni, G., Chapot, B., Hall, A. J., Wogan, G. N., Whittle, H., Montesano, R., and Groopman, J. D. (1992). Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev. 1, 229-234.
125. Wild, C. P., and Turner, P. C. (2002). The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17, 471-481.
126. Williams, D. E., Orner, G., Willard, K. D., Tilton, S., Hendricks, J. D., Pereira, C., Benninghoff, A. D., and Bailey, G. S. (2009). Rainbow trout (Oncorhynchus mykiss) and ultra-low dose cancer studies. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 149, 175-181.
127. Wogan, G. N., Paglialunga, S., and Newberne, P. M. (1974). Carcinogenic effects of low dietary levels of aflatoxin B1 in rats. Food Cosmet. Toxicol. 12, 681-685.
128. Wu, F. (2004). Mycotoxin risk assessment for the purpose of setting international regulatory standards. Environ. Sci. Technol. 38, 4049-4055.
129. Wu, F., and Khlangwiset, P. (2010). Health economic impacts and costeffectiveness of aflatoxin-reduction strategies in Africa: case studies in biocontrol and post-harvest interventions. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 27, 496-509.
130. Yang, C. S., Lambert, J. D., Hou, Z., Ju, J., Lu, G., and Hao, X. (2006). Molecular targets for the cancer preventive activity of tea polyphenols. Mol. Carcinog. 45, 431-435.
131. Yates, M. S., Kwak, M. K., Egner, P. A., Groopman, J. D., Bodreddigari, S., Sutter, T. R., Baumgartner, K. J., Roebuck, B. D., Liby, K. T., Yore, M. M., et al. (2006). Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res. 66, 2488-2494.
132. Yeh, F. C., Mo, C. C., and Ren, R. C. (1985). Risk factors for hepatocellular carcinoma in Guangxi, People's Republic of China. Natl. Cancer Inst. Monogr. 69, 47-48.
133. Yeh, F. S., Yu, M. C., Mo, C. C., Luo, S., Tong, M. J., and Henderson, B. E. (1989). Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 49, 2506-2509.
134. Yu, J., Cleveland, T. E., Nierman, W. C., and Bennett, J. W. (2005). Aspergillus flavus genomics: gateway to human and animal health, food safety, and crop resistance to diseases. Rev. Iberoam Micol. 22, 194-202.
135. Yu, M. W., Lien, J. P., Chiu, Y. H., Santella, R. M., Liaw, Y. F., and Chen, C. J. (1997). Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J. Hepatol. 27, 320-330.
136. Zhang, Y., Talalay, P., Cho, C. G., and Posner, G. H. (1992). A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl Acad. Sci. U.S.A. 89, 2399-2403.